Chemcon Speciality Chemicals share price & results
- Sept 2026
- Sept 2026
Vadodara-based speciality chemicals manufacturer and world's 3rd largest HMDS producer, making organic chemicals (HMDS, CMIC, Bromobenzene, 2-Bromo) and inorganic bromides (Calcium, Zinc, Sodium Bromide) for pharma, agrochemical and oilfiel
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 65.5 | +21.9% YoY | Quarterly, as filed | Quarter to Sept 2026 | Revenue from operations as filed. |
| Operating margin | 16.9 | +4.1 pts YoY | Operating profit / revenue | Quarter to Sept 2026 | For the quarter; a change is in percentage points. |
| Net profit | 7.5 | +30.8% YoY | Quarterly, as filed | Quarter to Sept 2026 | Profit after tax as filed. |
| Return on equity | 6.26 | −0.1 pts | Trailing twelve months | TTM to Sept 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 13.70 | −0.1 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 22.25 | +38.4 pts | Trailing twelve months | TTM to Sept 2026 | Revenue change against the same period one year earlier. |
Price
Performance −23.5% 1Y
1Y: ₹248.15 on 24 Oct 2025 → ₹189.84. High ₹252.15 (29 Oct 2025), low ₹125.92 (30 Mar 2026).
- Previous close
- ₹187.51
- Market cap
- ₹691 Cr
- 52-week range
- ₹125.92 – ₹252.15
- One year
- −23.17%
- Price to earnings (TTM to Sept 2026)
- 23.08×
- Return on equity (TTM to Sept 2026)
- 6.26%
Overview
- Symbol
- NSE:CHEMCON
- Sector
- Chemicals
- Industry
- Commodities
- Exchange
- NSE
- Currency
- INR
What Chemcon Speciality Chemicals Limited does
Based on the company's own presentations, annual report and earnings calls.
Chemcon Speciality Chemicals manufactures organic chemicals (HMDS, CMIC, Bromobenzene, 2-Bromo) and inorganic bromides (Calcium Bromide, Zinc Bromide, Sodium Bromide) used as pharmaceutical intermediates, agrochemical/aromatic inputs and oilwell completion fluids. It is the only Indian manufacturer of HMDS and Zinc Bromide, the largest manufacturer of CMIC worldwide, and the largest manufacturer of Calcium Bromide in India. The company sells through both domestic and export channels, with exports (inclusive of deemed exports) reaching key markets such as the US, Japan, UAE, Italy, South Korea, Germany, China, Russia, Spain, Thailand and Malaysia. It also recently acquired Shivam Petrochem Industries via slump sale to add bulk drug intermediates such as Trityl Chloride, PTSCL, 2-CTC and TosMIC to its portfolio.
Segments
- Organic Chemicals
- Inorganic Chemicals
- Manufacturing plants
- 9 operational plants (Manjusar, Vadodara, Gujarat)
- Installed capacity - Organic Chemicals
- 11,400 MTPA (HMDS, CMIC, Bromobenzene, 2-Bromo and other ancillary products)
- Installed capacity - Inorganic Chemicals (Bromides)
- 15,000 MTPA
- Owned warehouses
- 6
- Proposed expansion units
- 2 (P-10, P-11) under process
- Employees
- 237 permanent employees (as of Mar 31, 2025)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +31% (quarter to sept 2026 against sept 2025).
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 54 | 55 | 54 | 54 | 57 | 75 | 66 | 65 |
| Expenses | 43 | 49 | 46 | 47 | 51 | 67 | 51 | 54 |
| Operating profit | 11 | 6 | 8 | 7 | 7 | 9 | 15 | 11 |
| Operating margin | 20.8% | 10.6% | 14.5% | 12.8% | 11.6% | 11.8% | 23.2% | 16.9% |
| Other income | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Interest | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | 12 | 5 | 8 | 8 | 7 | 9 | 15 | 10 |
| Tax rate | 25.7% | 26.9% | 24.2% | 27.7% | 25.0% | 27.5% | 24.7% | 25.7% |
| Net profit | 9 | 4 | 6 | 6 | 5 | 6 | 11 | 8 |
| EPS (₹ per share) | 2.41 | 1.08 | 1.74 | 1.57 | 1.39 | 1.74 | 2.99 | 2.05 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 303 | 267 | 207 | 240 |
| Expenses | 232 | 241 | 175 | 210 |
| Operating profit | 71 | 27 | 33 | 30 |
| Other income | 13 | 14 | 14 | 15 |
| Interest | 1 | 4 | 4 | 2 |
| Depreciation | 8 | 11 | 11 | 12 |
| Profit before tax | 74 | 26 | 33 | 32 |
| Net profit | 55 | 19 | 24 | 24 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 | Sept 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 37 | 37 | 37 | 37 | 37 | 37 |
| Reserves | 421 | 440 | 464 | 476 | 447 | 441 |
| Borrowings | 64 | 43 | 25 | 0 | 53 | 27 |
| Other liabilities | 32 | 26 | 29 | 35 | 32 | 33 |
| Total liabilities | 553 | 545 | 554 | 548 | 568 | 538 |
| Fixed assets | 141 | 146 | 149 | 144 | 195 | 190 |
| Capital work in progress | 14 | 42 | 40 | 47 | 21 | 21 |
| Investments | 0 | 0 | 10 | 11 | 10 | 11 |
| Other assets | 398 | 356 | 355 | 346 | 342 | 316 |
| Total assets | 553 | 545 | 554 | 548 | 568 | 538 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 65 | 74 | 13 | 12 | 38 | 42 |
| Cash from investing | -152 | -92 | -16 | -25 | -17 | -35 |
| Cash from financing | 111 | 30 | 12 | -25 | -22 | -3 |
| Net cash flow | 23 | 11 | 9 | -37 | 0 | 3 |
| Free cash flow | 34 | 24 | -32 | -31 | 29 | 32 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 142 | 146 | 81 | 112 | 91 | 97 |
| Inventory days | 175 | 102 | 164 | 119 | 261 | 158 |
| Days payable | 67 | 70 | 44 | 23 | 49 | 42 |
| Cash conversion cycle | 250 | 177 | 201 | 208 | 303 | 212 |
| Working capital days | 184 | 105 | 108 | 162 | 211 | 108 |
| Return on capital employed | 29.0% | 21.0% | 15.0% | 6.0% | 7.0% | 6.0% |
| Dividend payout | 0.0% | 0.0% | 27.0% | 0.0% | 0.0% | 101.0% |
What the price assumes
Growth trapTo justify its price of ₹190, this stock must grow earnings at 21% every year for 7 years. Our analysis caps realistic growth at ~-25%. At that growth it is worth ₹17 — downside of 91%.
- Growth the price implies
- 20.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- -24.6% a year
- net profit, FY23–FY26 · EPS -24.6%
- The gap
- 0.5 pp
- -91% downside if it only repeats history
Ownership
Who owns it
Promoters hold 74.47% as of Sept 2026; institutions added 0.00 pts since Jun 2026.
- Promoters 74.47%
- Foreign institutions 0.25%
- Domestic institutions 0.00%
- Public 25.29%
Who is on the register
Named in the Sep 2026 filing
Every holder of Chemcon Speciality Chemicals Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 27.81% | unchanged | |
| 25.30% | unchanged | |
| 6.91% | unchanged | |
| 6.48% | unchanged | |
| 5.40% | unchanged | |
| 2.54% | unchanged | |
| 0.01% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Chemcon Speciality Chemicals Limited
Free account: one company. Everything above stays public.
Write why you follow Chemcon Speciality Chemicals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Chemicals companies
Learn to analyse Chemcon Speciality Chemicals Limited
Guides on how to read this kind of business and the numbers that matter.







